(Q43746128)

26 November 2017

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome (English)

1 reference

26 November 2017

0 references

1 reference

T Lembo

1

1 reference

26 November 2017

R A Wright

2

1 reference

26 November 2017

B Bagby

3

1 reference

26 November 2017

C Decker

4

1 reference

26 November 2017

S Gordon

5

1 reference

26 November 2017

P Jhingran

6

1 reference

26 November 2017

E Carter

7

1 reference

26 November 2017

Lotronex Investigator Team

8

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

The American Journal of Gastroenterology

26 November 2017

1 reference

26 November 2017

96

1 reference

26 November 2017

2662-2670

1 reference

26 November 2017

9

1 reference

A national survey of practice patterns of gastroenterologists with comparison to the past two decades

26 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Clinical economics review: irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Irritable bowel syndrome clinical trial design: future needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

5-HT (serotonin) physiology and related drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.04128.X

10.1111/J.1572-0241.2001.04128.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference